![](https://pharmashots.com/public/default-image/default-730x400.png )
Takeda Amend its Collaboration with Wave Life Sciences to Advance CNS Programs
Shots:
- Wave to receive $22.5M for research & preclinical expenses and is eligible to receive opt-in payment- development & commercial milestone & will lead the manufacturing & joint clinical co-development activities. Both companies will share global costs & 50:50 profits
- Takeda’s gets an option to co-develop & co-commercialize CNS therapies for 3 targets- C9orf72- HTT & ATXN3- including WVE-004/003 & will lead the joint co-commercial activities in the US & all commercial activities outside of the US
- Takeda discontinues its discovery research with Wave for CNS programs & Takeda gets the right to license multiple preclinical programs for CNS indications over 4 yrs. research term
Ref: Globe Newswire | Image:Takeda
Click here to read the full press release
Tags
![](https://pharmashots.com/public/images/Senior-2023-08-17-64ddc3af74ec4.png)
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com